BIT:1LLY - US5324571083 - Common Stock
The current stock price of 1LLY.MI is 624.7 EUR. In the past month the price decreased by -8.52%. In the past year, price decreased by -13.89%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY.DE | ELI LILLY & CO | 45.43 | 596.36B | ||
ZEG.DE | ASTRAZENECA PLC | 18.05 | 424.30B | ||
JNJ.DE | JOHNSON & JOHNSON | 17.77 | 367.56B | ||
RHO.DE | ROCHE HOLDING AG-BR | 14.17 | 240.83B | ||
NOV.DE | NOVO NORDISK A/S-B | 14.42 | 213.95B | ||
NOT.DE | NOVARTIS AG-REG | 14.44 | 209.65B | ||
SAN.PA | SANOFI | 11.3 | 207.99B | ||
SNW.DE | SANOFI | 11.2 | 206.16B | ||
1SAN.MI | SANOFI | 11.19 | 205.99B | ||
1MRKX.MI | MERCK & CO. INC. | 11.06 | 182.59B | ||
6MK.DE | MERCK & CO. INC. | 11.04 | 182.34B | ||
PFE.DE | PFIZER INC | 7.36 | 121.73B |
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 47,000 full-time employees. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. The company is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD).
ELI LILLY & CO
Lilly Corporate Ctr, Drop Code 1094
Indianapolis INDIANA US
Employees: 47000
Phone: 13172762000
The current stock price of 1LLY.MI is 624.7 EUR. The price increased by 0.87% in the last trading session.
The exchange symbol of ELI LILLY & CO is 1LLY and it is listed on the Euronext Milan exchange.
1LLY.MI stock is listed on the Euronext Milan exchange.
33 analysts have analysed 1LLY.MI and the average price target is 764.85 EUR. This implies a price increase of 22.43% is expected in the next year compared to the current price of 624.7. Check the ELI LILLY & CO stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ELI LILLY & CO (1LLY.MI) has a market capitalization of 591.25B EUR. This makes 1LLY.MI a Mega Cap stock.
ELI LILLY & CO (1LLY.MI) currently has 47000 employees.
ELI LILLY & CO (1LLY.MI) has a support level at 622.76 and a resistance level at 638.81. Check the full technical report for a detailed analysis of 1LLY.MI support and resistance levels.
The Revenue of ELI LILLY & CO (1LLY.MI) is expected to grow by 36.89% in the next year. Check the estimates tab for more information on the 1LLY.MI EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ELI LILLY & CO (1LLY.MI) has a dividend yield of 0.82%. The yearly dividend amount is currently 4.23. Check the full fundamental report for a detailed analysis of 1LLY.MI dividend history, reliability and sustainability.
ELI LILLY & CO (1LLY.MI) will report earnings on 2025-10-30, before the market open.
The PE ratio for ELI LILLY & CO (1LLY.MI) is 45.04. This is based on the reported non-GAAP earnings per share of 13.87 and the current share price of 624.7 EUR. Check the full fundamental report for a full analysis of the valuation metrics for 1LLY.MI.
ChartMill assigns a fundamental rating of 6 / 10 to 1LLY.MI. While 1LLY.MI has a great profitability rating, there are some minor concerns on its financial health.
Over the last trailing twelve months 1LLY.MI reported a non-GAAP Earnings per Share(EPS) of 13.87. The EPS increased by 77.67% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 25.91% | ||
ROA | 13.67% | ||
ROE | 75.52% | ||
Debt/Equity | 1.87 |
33 analysts have analysed 1LLY.MI and the average price target is 764.85 EUR. This implies a price increase of 22.43% is expected in the next year compared to the current price of 624.7.
For the next year, analysts expect an EPS growth of 76.85% and a revenue growth 36.89% for 1LLY.MI